Close-up of a Lenacapavir vaccine vial in a medical setting, highlighting pharmaceutical preparation.
In a major win for global health, Gilead Sciences has agreed to supply its groundbreaking HIV prevention jab, lenacapavir, at low cost to up to two million people in low-income countries, primarily in Africa. Hailed as 2024’s biggest HIV breakthrough, lenacapavir offers up to six months of protection from HIV in a single injection. While further research is needed, early clinical trials suggest the drug may last up to twelve months. This will make it significantly more effective than current pre-exposure prophylaxis medications. Lenacapavir costs over $28,000 in the US, but Gilead’s deal with the Global Fund brings hope to millions who couldn’t afford it as the deal significantly reduces the price. However, experts warn that the drug’s two-million-dose cap is far too low, especially amid US aid cuts that threaten HIV response efforts.
The Telegraph